



International PfSPZ Consortium Meeting
Muskoka Conference Room (Rostie Group)
20 Bay St., 11th Floor - WaterPark Place
Toronto, ON, Canada

Day 1: Saturday 08 November 2025

Time	Talk Title	Presenter(s)
10:45	Log on to Zoom	
11:00	Welcome	Kim Lee Sim / Sumana Chakravarty / Tom Richie
11:05	Logistics	Yonas Abebe / Natasha KC
11:10	Introduction: "The desperate need for innovation to win the battle against malaria"	Stephen Hoffman
	Directions for PfSPZ vaccines	
11:25	NIH perspective and plans on malaria vaccine development [cancelled due to government shut-down]	Annie Mo
11:35	Gates Foundation perspective on malaria vaccine development	Chris Ockenhouse
11:45	Pre-conception maternal immunization with PfSPZ Vaccine protects infants against Pf malaria	Halimatou Diawara
12:00	Discussion	Moderators: Peter Kremsner, Patrick Duffy
12:10	WORKING LUNCH	
	Making a better vaccine	
12:25	Introduction: the theoretical limitations of PfSPZ-LARC2 Vaccine	Stephen Hoffman
12:35	Pan-African hybrid PfSPZ-LARC2 Vaccine	Lucia Pazzagli
12:50	Pan-continental hybrid PfSPZ-LARC2 Vaccine	Kim Lee Sim
13:00	Using genetic crosses to map genes necessary for enhanced vaccine efficacy	Ashley Vaughan
13:10	Discussion	Moderators: Moriya Tsuji, Miguel Prudêncio
13:25	An NKT cell agonist 7DW8-5 as an adjuvant for SPZ-based vaccines and GMP manufacture for clinical use	Sumana Chakravarty / Kim Lee Sim / Moriya Tsuji
13:40	Transgenic PySPZ and PfSPZ as vaccines and immunotherapeutics	Ehud Inbar and Debashree Goswami (remote)
13:50	Transgenic <i>P. yoelii</i> as vaccines with focus on immune modulation	Tonny Owalla (remote)
14:00	Discussion	Moderators: Scott Miller, Rolf Fendel
	Immunology, biomarker, new immunogen identification and model systems	
14:15	<i>Aotus lemurinus griseimembra</i> : PfSPZ infection, PfSPZ-LARC2 Vaccine protection and immunology	Faith Onditi and Nicholas Poulton (Patrick Duffy)
14:25	Systems serology identification of biomarkers of protection in PfSPZ vaccine trials and PkSPZ-immunized non-human primates	Jonathan Herman
14:35	Clonotypic, phenotypic, and functional profiling of protection-associated <i>P. falciparum</i> -specific CD4 T cells after irradiated sporozoite vaccination (Warfighter-3)	Alexandra Donlan
14:45	Use of PkSPZ and non-human primates to identify biomarkers of protection	Sumana Chakravarty
14:55	Identification of biomarkers of protection in non-human primates immunized with Pk, Pf and PvSPZ vaccines	Brandon Wilder
15:08	A discovery pipeline for novel CD8+ T cell targets following SPZ immunization	Jake Baum
15:18	Discussion	Moderators: Takafumi Tsuboi
15:33	COFFEE BREAK	
15:48	Consortium Group Photograph	
	Monoclonal antibody development	
15:53	Current status of anti-PfCSP human mAb development at VRC, NIH, with emphasis on L9LS	Bob Seder (remote)
16:03	Current status of anti-PfCSP human mAb development at Gates MRI	Scott Miller
16:13	Current status of development of anti-PfCSP human mAbs with 10x to 1000x increased affinity	Sumana Chakravarty
16:23	Discussion	Moderators: Kirsten Lyke, James McCarthy
	In vitro PfSPZ production	
16:38	Current status of <i>in vitro</i> PfSPZ development at MalarVX	Marion Avril
16:48	Current status of <i>in vitro</i> PfSPZ development at Sanaria	Stephen Hoffman
16:58	Discussion	Moderators: Ashley Vaughan, Emily Locke
	Travel medicine indication	
17:08	How the results of trial in Indonesian soldiers further inform the travel medicine indication	Tom Richie
17:18	Discussion	Moderators: Peter Kremsner
	Other interesting developments	
17:23	Anopheles gambiae mosquito bite CHMI from local isolates in Lambaréné, Gabon	Steffen Borrmann
17:33	Failure of ACTs for treating <i>Plasmodium falciparum</i> in travelers to Africa	Eli Schwartz
17:43	Challenges raised by FDA for using qPCR to diagnose malaria: update on the Seattle experience	Sean Murphy (remote)
17:53	Discussion	Moderators: Regina Rabinovich, Richard Steketee
18:03	Open discussion	Stephen Hoffman
18:18	Adjourn	
19:00	Dinner: 7:00 PM	



International PfSPZ Consortium Meeting

Muskoka Conference Room (Rostie Group)

20 Bay St., 11th Floor - WaterPark Place

Toronto, ON, Canada

Day 2: Sunday 09 November 2025

Time		
7:30	Coffee and bagels	
7:45	Log on to Zoom	
8:00	Introduction to the day	Stephen Hoffman
8:05	WHO update: status of malaria vaccine introduction and pipeline	Rafiq Okine
PfSPZ-LARC2 Vaccine		
8:15	Introduction and overview of PfSPZ-LARC2 Vaccine	Stefan Kappe
8:25	BFSPZL1: completed first-in-humans age de-escalation trial in Burkina Faso (45- to 1-year-	Sodiomon Sirima
8:40	BFSPZL1: results of identity assay to distinguish field infections from vaccine	Debashree Goswami
8:47	BFSPZL1: results of antibody assays	Natasha KC
8:54	BFSPZL1: plans for evaluating cellular immunity	Stephen Hoffman for Nana Minkah
9:01	BFSPZL1: plans for systems serology	Jonathan Herman (remote)
9:08	Discussion	Moderators: Matt Laurens, James Kublin
9:23	USSPZL1 (U Wash, Seattle): trial design, early results and plans for immunology	Jim Kublin
9:35	DESPZL1 (U of Tübingen): trial design, plans for initiation and timeline	Andrea Kreidenweiss (remote)
9:45	Clinical Development Plan for PfSPZ-LARC2 Vaccine	Tom Richie
9:55	BFSPZL2 (GRAS, Burkina Faso): phase 2 trial design	Tom Richie, Sodiomon Sirima
10:02	USSPZL2 (U Maryland): trial design (including MAL31 CHMI optimization)	Andrea Berry / Kirsten Lyke
10:09	Phase 2 Trial of the PfSPZ-LARC2 Malaria Vaccine in Women of Reproductive Age in	Martina Oneko, Victor Akelo
10:14	GA2 (Leiden UMC): Exploring the protective potential of GA2 and its immune response	Blandine Franke-Fayard
10:24	Discussion	Moderators: Patrick Duffy
10:39	COFFEE BREAK	
10:54	Consortium Group Photograph	
Plasmodium vivax		
10:59	Progress on P. berghei-based vaccination against P. vivax	Miguel Prudêncio
11:09	Producing PvSPZ Challenge from infected humans	John Woodford
11:19	Producing PvSPZ Challenge from humans and infected non-human primates	Sumana Chakravarty
11:29	Discussion:	Moderators: Brandon Wilder, Carsten Köhler
11:44	Open Discussion: how do we ever achieve licensure and fielding of a vaccine that prevents malaria infection in 90% of recipients for a year, meeting WHO Strategic Goal #1, with emphasis on realistic funding requirements?	Moderators: Stephen Hoffman, Peter Kremsner, Stefan Kappe
11:59	Closing the meeting	Stephen Hoffman, Tom Richie
12:00	Adjourn	